HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma

Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HB...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 50; no. 4; pp. 1121 - 1129
Main Authors Park, Hyunsung, Kim, Do Young, Kim, Soo-Jeong, Chung, Haerim, Cho, Hyunsoo, Jang, Ji Eun, Cheong, June-Won, Min, Yoo Hong, Song, Jae-Woo, Kim, Jin Seok
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.10.2018
대한암학회
Subjects
Adolescent
Adult
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Hepatitis B - epidemiology
Hepatitis B Core Antigens - metabolism
Hepatitis B Surface Antigens - metabolism
Hepatitis B virus - immunology
Humans
Lymphoma - immunology
Lymphoma - therapy
Male
Middle Aged
Multiple Myeloma - immunology
Multiple Myeloma - therapy
Original
Retrospective Studies
Virus Activation
Young Adult
의약학
Stem cell transplantation
HBV-related hepatitis
Hepatitis B core antibody
Lymphoma
Multiple myeloma
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2017.329

Cover

Abstract Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
AbstractList Purpose Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)– negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis. KCI Citation Count: 0
Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma.PURPOSEAlthough hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma.We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma.MATERIALS AND METHODSWe retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma.Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT.RESULTSThree patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT.Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.CONCLUSIONOur data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
Author Kim, Do Young
Jang, Ji Eun
Kim, Jin Seok
Park, Hyunsung
Chung, Haerim
Cheong, June-Won
Kim, Soo-Jeong
Song, Jae-Woo
Cho, Hyunsoo
Min, Yoo Hong
Author_xml – sequence: 1
  givenname: Hyunsung
  surname: Park
  fullname: Park, Hyunsung
– sequence: 2
  givenname: Do Young
  surname: Kim
  fullname: Kim, Do Young
– sequence: 3
  givenname: Soo-Jeong
  surname: Kim
  fullname: Kim, Soo-Jeong
– sequence: 4
  givenname: Haerim
  surname: Chung
  fullname: Chung, Haerim
– sequence: 5
  givenname: Hyunsoo
  surname: Cho
  fullname: Cho, Hyunsoo
– sequence: 6
  givenname: Ji Eun
  surname: Jang
  fullname: Jang, Ji Eun
– sequence: 7
  givenname: June-Won
  surname: Cheong
  fullname: Cheong, June-Won
– sequence: 8
  givenname: Yoo Hong
  surname: Min
  fullname: Min, Yoo Hong
– sequence: 9
  givenname: Jae-Woo
  surname: Song
  fullname: Song, Jae-Woo
– sequence: 10
  givenname: Jin Seok
  surname: Kim
  fullname: Kim, Jin Seok
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29198097$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002392821$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptksFuEzEQhi1URNPCjTPyEaRusL279vqClERAKqWAQuBqOV5vauJdL7a3Um59hz4PL8OT4DRtVRDyYaSZb_6xZv4TcNS5TgPwEqNxgYv8rfJxTBBm45zwJ2BEECozTkp6BEa45FVGOK-OwUkIPxCiRc7wM3BMOOYV4mwEfs2nYbLJPumNjOZKn8FJF002n6rf1zf3SfglBd3FAL9GYy2cy5STcGnCFroGznWf6tEEOIXfjR9Cal1qK6OuH9VkE7WHkyE66zZu2GvpFs500lt52YXeyi4m1nWwcR5eDDaa3mp4sdPWtRLuc9KaTZcwuNi1_WXKPgdPG2mDfnEXT8G3D-9Xs3m2-PzxfDZZZKooipgxTjmlpKa0LqkipFCU0ZKsla7S07qq11JyztZSqxoxnVOmKsbWCtOyKRqSn4I3B93ON2KrjHDS3MaNE1svJsvVucgZ5RWvEvvuwPbDutW1Sovz0orem1b63W3n35XOXCadK0ExJxyVSeD1nYB3PwcdomhNUGlRstNpcQJzRnKEUblHXz2e9TDk_r4JODsAyrsQvG4eEIzE3j4i2Ufs7SOSfRJO_sGVORwl_dTY_zf9Af8RzpE
CitedBy_id crossref_primary_10_1080_23744235_2019_1693624
crossref_primary_10_1111_jgh_15640
Cites_doi 10.1016/j.clim.2008.01.011
10.1007/s12072-012-9365-4
10.1016/j.bbmt.2006.11.019
10.3109/10428194.2014.947606
10.1002/hep.26718
10.3904/kjim.2013.28.4.413
10.1111/liv.12882
10.1200/JCO.2014.56.7081
10.1038/nrgastro.2013.216
10.1002/hep.23190
10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
10.3109/10428194.2014.964699
10.1002/jmv.21862
10.1007/s11901-015-0269-3
10.1007/s12185-010-0592-y
10.1046/j.1423-0410.2001.00016.x
10.5045/br.2015.50.1.51
10.1007/s00705-009-0559-6
10.1111/hepr.12603
10.3748/wjg.v16.i14.1765
10.1200/JCO.2008.18.0182
ContentType Journal Article
Copyright Copyright © 2018 by the Korean Cancer Association 2018
Copyright_xml – notice: Copyright © 2018 by the Korean Cancer Association 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2017.329
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 1129
ExternalDocumentID oai_kci_go_kr_ARTI_3769898
PMC6192905
29198097
10_4143_crt_2017_329
Genre Journal Article
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
08R
ID FETCH-LOGICAL-c444t-7969662d66d56c224c67652bce8e8eee8dbaa997baecd07e367c877bc165f4f23
ISSN 1598-2998
2005-9256
IngestDate Tue Nov 21 21:30:57 EST 2023
Thu Aug 21 14:08:06 EDT 2025
Thu Jul 10 23:14:04 EDT 2025
Thu Jan 02 23:02:09 EST 2025
Tue Jul 01 03:18:47 EDT 2025
Thu Apr 24 22:56:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Stem cell transplantation
HBV-related hepatitis
Hepatitis B core antibody
Lymphoma
Multiple myeloma
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c444t-7969662d66d56c224c67652bce8e8eee8dbaa997baecd07e367c877bc165f4f23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This study was presented in the form of a poster presentation at the 56th annual meeting of the American Society of Hematology in San Francisco, CA on December 6-9, 2014.
Hyunsung Park and Do Young Kim contributed equally to this work.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC6192905
PMID 29198097
PQID 1972301055
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_3769898
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6192905
proquest_miscellaneous_1972301055
pubmed_primary_29198097
crossref_primary_10_4143_crt_2017_329
crossref_citationtrail_10_4143_crt_2017_329
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-10-01
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2018
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref12
ref23
ref15
ref14
ref20
ref11
ref22
ref21
ref2
ref1
ref17
(ref7) 2012
ref16
ref19
Guillaume (ref10) 1998
ref18
ref8
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref22
  doi: 10.1016/j.clim.2008.01.011
– ident: ref8
  doi: 10.1007/s12072-012-9365-4
– start-page: 167
  volume-title: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
  year: 2012
  ident: ref7
– ident: ref20
  doi: 10.1016/j.bbmt.2006.11.019
– ident: ref14
  doi: 10.3109/10428194.2014.947606
– ident: ref15
  doi: 10.1002/hep.26718
– ident: ref23
  doi: 10.3904/kjim.2013.28.4.413
– ident: ref17
  doi: 10.1111/liv.12882
– ident: ref21
  doi: 10.1200/JCO.2014.56.7081
– ident: ref2
  doi: 10.1038/nrgastro.2013.216
– ident: ref3
  doi: 10.1002/hep.23190
– ident: ref6
  doi: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
– ident: ref1
  doi: 10.3109/10428194.2014.964699
– start-page: 1471
  volume-title: Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
  year: 1998
  ident: ref10
– ident: ref16
  doi: 10.1002/jmv.21862
– ident: ref18
  doi: 10.1007/s11901-015-0269-3
– ident: ref5
  doi: 10.1007/s12185-010-0592-y
– ident: ref12
  doi: 10.1046/j.1423-0410.2001.00016.x
– ident: ref4
  doi: 10.5045/br.2015.50.1.51
– ident: ref13
  doi: 10.1007/s00705-009-0559-6
– ident: ref19
  doi: 10.1111/hepr.12603
– ident: ref9
  doi: 10.3748/wjg.v16.i14.1765
– ident: ref11
  doi: 10.1200/JCO.2008.18.0182
SSID ssj0064371
Score 2.1249118
Snippet Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)-negative patients are not considered to be at risk for hepatitis B...
Purpose Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)– negative patients are not considered to be at risk for...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1121
SubjectTerms Adolescent
Adult
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Hepatitis B - epidemiology
Hepatitis B Core Antigens - metabolism
Hepatitis B Surface Antigens - metabolism
Hepatitis B virus - immunology
Humans
Lymphoma - immunology
Lymphoma - therapy
Male
Middle Aged
Multiple Myeloma - immunology
Multiple Myeloma - therapy
Original
Retrospective Studies
Virus Activation
Young Adult
의약학
Title HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma
URI https://www.ncbi.nlm.nih.gov/pubmed/29198097
https://www.proquest.com/docview/1972301055
https://pubmed.ncbi.nlm.nih.gov/PMC6192905
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002392821
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2018, 50(4), , pp.1121-1129
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCO Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: ABDBF
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: DIK
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: 5-W
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: RPM
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtowFLb6I027mfZf9idv2q6ydJA4CbkEuiqrRjWNdupd5DiGRoWkgnDRXe0d9jx7mT3JznHsEBCTtgoJkOPEwPmwz4m_8x1C3sqEM0-0uS3dhNlMMG7z1JM2c8ewoEBI4gnMRh6e-tE5O7nwLnZ2DxqspWWZHIrvW_NKbmNVaAO7Ypbsf1i2vig0wHuwLzyDheH5n2wc9Re9iX0qJ0q9W2sBZHbUF4bD4JqDqMWfqWy2UZlNp1aEVYe49VUzyyOJzOoyW1h961s2Xy7qCyi2HHilqx5VWfHeUlW-RQbtqJQza4A3ASup9CnPGxzGoaEsDm_ktJhxZMAPwfufIAXH-nwDcCr04rBSTBAwgtYhqlLvakL8as-rInlHN8t8sdTrL6_LQx8VlprINppHRWGfyGLVPrjUs13EUXijeROk063pdDqloJjjvoX-eJvA1jN7iOkmVcnrQ6nalAxr6FTK5mY5qHRwNexZY24Hz7TT8BPQUd22BjHwQAE4Yo5M3U5w6K53AwRdzxQenbATdtsVO3lD8_vLcICBbYjivPtO4PvOHtnv9Y_6x8bLwP3WSgtYf60qqQMH_9AcGsWu9ThrntduPh9vC6o2ucENZ-vsPrmnoyTaqyD_gOzI_CG5M9Q8kEfk1zry31OD-98_fppGahBPFeIpIp5yioinxZjWeKZ9qhAPp2qsN44prNMV1ilinSLW6QbWKWCdGqxTjXWKbQbr1GD9MTk__ng2iGxdiMQWjLHSDlBCyndS3089X4DTK_zA95xEyC48pOymCedhGCRcirQdSNcPRDcIEtHxvTEbO-4TspcXuTwglGPM4QoU3gRf3nHDdhqw1BEi9JjvBOMWsYyRYqFV-rFYzDSGaB2tG4N1Y7RuDNZtkXd17-tKneYv_d6AveMrkcUoJ4-vkyK-mscQNH-KwcfAKrIt8trAIYY1BjcOeS7hp41VaUJVSrdFnlbwqIcz6GqRYA04dQcccP1Inl0qHXsN8We3PvM5ubuaDF6QvXK-lC8hRiiTV_rv8gfWjRmp
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HBsAg-Negative%2C+Anti-HBc%E2%80%93Negative+Patients+Still+Have+a+Risk+of+Hepatitis+B+Virus%E2%80%93Related+Hepatitis+after+Autologous+Stem+Cell+Transplantation+for+Multiple+Myeloma+or+Malignant+Lymphoma&rft.jtitle=Cancer+research+and+treatment&rft.au=Park%2C+Hyunsung&rft.au=Kim%2C+Do+Young&rft.au=Kim%2C+Soo-Jeong&rft.au=Chung%2C+Haerim&rft.date=2018-10-01&rft.pub=Korean+Cancer+Association&rft.issn=1598-2998&rft.eissn=2005-9256&rft.volume=50&rft.issue=4&rft.spage=1121&rft.epage=1129&rft_id=info:doi/10.4143%2Fcrt.2017.329&rft_id=info%3Apmid%2F29198097&rft.externalDocID=PMC6192905
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon